Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

Tsukamoto, Atsushi; Ohno, Koichi; Maeda, Shingo; Nakashima, Ko; Fukushima, Kenjiro; Fujino, Yasuhito; Tsujimoto, Hajime

doi:10.1292/jvms.11-0270

Cited by 16 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, good correlation between the sonographic MI and GE assessed by the 13 C‐octanoic acid breath test has been reported in dogs . The sonographic assessment of the MI has been used to assess the effects of antiemetic drugs on antral motility and GE as well as the effects of various prokinetics in healthy dogs . The results of this study support the potential usefulness of the MI to assess the effects of pharmacologic agents on antral motility and GE in cats.…”

Section: Discussionsupporting

confidence: 74%

Validation of Ultrasonography for Assessment of Gastric Emptying Time in Healthy Cats by Radionuclide Scintigraphy

Husník

Fletcher

Gaschen

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundThe prevalence of gastric emptying (GE) disorders in cats is unknown due to lack of clinically applicable diagnostic tests.ObjectivesThe principal aim of this study was to assess correlation between scintigraphic and ultrasonographic measurements of GE time (GET) in healthy cats. Additionally, variability of ultrasonographic GET, and correlation between scintigraphy and ultrasonographic parameters of gastric motility were evaluated.AnimalsEight healthy domestic shorthair cats.MethodsProspective study. Scintigraphic GET was determined using a solid test meal containing 4 mCi 99mTc‐mebrofenin. Each cat had 3 separate ultrasonographic assessments of GE, performed independent of scintigraphic assessment, after solid test meal consumption. The motility index (MI) of antral contractions was plotted against time and time for each fraction of the area under the MI curve determined. Ultrasonographic GET and MI were correlated to scintigraphic GET.ResultsScintigraphic GET (mean ± SD) for 25, 50, and 75% GE was 103 ± 32 minutes, 196 ± 45 minutes, and 288 ± 62 minutes, whereas sonographic GET for 25, 50, and 75% GE was 106 ± 13 minutes, 203 ± 19 minutes, and 305 ± 27 minutes. There was good correlation between scintigraphic and sonographic GET (r = 0.72–0.82) at 45–90% fractional GE and between scintigraphic GET and time of corresponding MI curve fraction (r = 0.78–0.86) at 40–90% fraction of the MI curve. There was moderate intraindividual variability for sonographic GET and MI curve fraction times as well as significant variation among individuals.Conclusions and clinical importanceUltrasonography is a valid alternative to scintigraphy for assessment of solid‐phase GE and allows assessment of postprandial gastric motility in healthy cats.

show abstract

Section: Discussionsupporting

confidence: 74%

Validation of Ultrasonography for Assessment of Gastric Emptying Time in Healthy Cats by Radionuclide Scintigraphy

Husník

Fletcher

Gaschen

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Since cisapride was withdrawn from the market for its cardiac arrhythmia side effect, mosapride has been used as a prokinetic agent for the treatment of dyspeptic symptoms of gastrointestinal disorders such as chronic gastritis, functional dyspepsia, irritable bowel syndrome, and gastric esophageal reflux disease [5,17]. Mosapride also enhances upper gastrointestinal motility in dogs [29,33] and has been approved as a prokinetic agent for canines in Japan. We have previously demonstrated that mosapride is effective for treating vincristine-induced gastric motility disorder in dogs [28].…”

mentioning

confidence: 99%

Effect of Mosapride on Prednisolone-Induced Gastric Mucosal Injury and Gastric-Emptying Disorder in Dog

Tsukamoto

Ohno

Maeda

et al. 2012

The Journal of Veterinary Medical Science

Self Cite

View full text Add to dashboard Cite

ABSTRACT. Previous report demonstrated that prokinetic agent mosapride has anti-ulcerogenic action in rat-indomethacin gastric mucosal injury model. Here, we assessed the prophylactic effect of mosapride on gastric mucosal injury and emptying disorder induced by prednisolone in dogs. Crossover study design was employed. Six healthy beagles were administered prednisolone alone (2 mg/kg, twice a day [BID] subcutaneously) and prednisolone with mosapride (1 mg/kg, BID, orally), followed by an interval of at least 6 weeks. In each treatment, gastric mucosal injury was scored endoscopically according to the modified Lanza scale, and gastric emptying was assessed with 13 C-octanoic acid breath test. The incidence of gastrointestinal adverse events was also investigated. Coadministration of mosapride with prednisolone significantly (P<0.05) reduced the gastric mucosal injury score (mean ± SD, 17.67 ± 6.96), compared with that of prednisolone treatment alone (25.50 ± 13.03). Prednisolone treatment delayed the half-emptying time (184 ± 45 min) compared with that of controls (137 ± 19 min), and coadministration of mosapride improved this gastric-emptying delay (143 ± 29 min). Furthermore, the incidence of the gastrointestinal adverse event vomiting became less frequent upon coadministration with mosapride. In addition to its prokinetic action, our study suggests that mosapride has an anti-ulcerogenic action in dogs. The use of mosapride in combination with prednisolone is effective for attenuating prednisolone-induced gastrointestinal adverse events. The corticosteroid prednisolone has been widely used for treating immune-mediated diseases such as immune-mediated hemolytic anemia, idiopathic polyarthritis, and atopic dermatitis [2,18,19]. However, this drug may cause gastric mucosal injury when administered at high doses [22]. Moreover, a previous study indicated that prednisolone can alter gastrointestinal motility [21,22] Mosapride, a selective 5-hydroxytryptamine-4 receptor (5-HT 4 R) agonist, promotes the release of acetylcholine in enteric nerves by activating 5-HT 4 R and thereby enhancing gastrointestinal motility [5,17]. Since cisapride was withdrawn from the market for its cardiac arrhythmia side effect, mosapride has been used as a prokinetic agent for the treatment of dyspeptic symptoms of gastrointestinal disorders such as chronic gastritis, functional dyspepsia, irritable bowel syndrome, and gastric esophageal reflux disease [5,17]. Mosapride also enhances upper gastrointestinal motility in dogs [29,33] and has been approved as a prokinetic agent for canines in Japan. We have previously demonstrated that mosapride is effective for treating vincristine-induced gastric motility disorder in dogs [28].In addition to its prokinetic action, recent findings suggest that mosapride mediates novel actions through 5-HT 4 R. Fujisawa et al. [7] demonstrated that mosapride attenuated gastric mucosal damage in a rat indomethacin gastric mucosal injury model. They demonstrated that this anti-ulcerogenic action of mosapride ...

show abstract

“…Mosapride is a novel 5‐HT 4 receptor agonist that enhances GI motility. It is used as a prokinetic in people and has recently been evaluated for use in dogs . Tegaserod, a potent partial 5‐HT 4 agonist and a weak 5‐HT 1D receptor agonist, has been shown to increase antral, duodenal, jejunal, and colonic motility in conscious dogs .…”

Section: Specific Pharmacological Interventionsmentioning

confidence: 99%

Gastrointestinal dysmotility disorders in critically ill dogs and cats

Whitehead

Cortes

Eirmann

2016

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objective -To review the human and veterinary literature regarding gastrointestinal (GI) dysmotility disorders in respect to pathogenesis, patient risk factors, and treatment options in critically ill dogs and cats. Etiology -GI dysmotility is a common sequela of critical illness in people and small animals. The most common GI motility disorders in critically ill people and small animals include esophageal dysmotility, delayed gastric emptying, functional intestinal obstruction (ie, ileus), and colonic motility abnormalities. Medical conditions associated with the highest risk of GI dysmotility include mechanical ventilation, sepsis, shock, trauma, systemic inflammatory response syndrome, and multiple organ failure. The incidence and pathophysiology of GI dysmotility in critically ill small animals is incompletely understood. Diagnosis -A presumptive diagnosis of GI dysmotility is often made in high-risk patient populations following detection of persistent regurgitation, vomiting, lack of tolerance of enteral nutrition, abdominal pain, and constipation. Definitive diagnosis is established via radioscintigraphy; however, this diagnostic tool is not readily available and is difficult to perform on small animals. Other diagnostic modalities that have been evaluated include abdominal ultrasonography, radiographic contrast, and tracer studies. Therapy -Therapy is centered at optimizing GI perfusion, enhancement of GI motility, and early enteral nutrition. Pharmacological interventions are instituted to promote gastric emptying and effective intestinal motility and prevention of complications. Promotility agents, including ranitidine/nizatidine, metoclopramide, erythromycin, and cisapride are the mainstays of therapy in small animals. Prognosis -The development of complications related to GI dysmotility (eg, gastroesophageal reflux and aspiration) have been associated with increased mortality risk. Institution of prophylaxic therapy is recommended in high-risk patients, however, no consensus exists regarding optimal timing of initiating prophylaxic measures, preference of treatment, or duration of therapy. The prognosis for affected small animal patients remains unknown. (J Vet Emerg

show abstract

Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

Cited by 16 publications

References 10 publications

Validation of Ultrasonography for Assessment of Gastric Emptying Time in Healthy Cats by Radionuclide Scintigraphy

Validation of Ultrasonography for Assessment of Gastric Emptying Time in Healthy Cats by Radionuclide Scintigraphy

Effect of Mosapride on Prednisolone-Induced Gastric Mucosal Injury and Gastric-Emptying Disorder in Dog

Gastrointestinal dysmotility disorders in critically ill dogs and cats

Contact Info

Product

Resources

About